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678Deep venous thrombosis after repair of nonruptured
abdominal aneurysm
Daniel L. Davenport, PhD,a and Eleftherios S. Xenos, MD, PhD,b Lexington, Ky
Objective: To examine venous thromboembolism (VTE) rates, timing, and risk factors after nonruptured open or
endoluminal abdominal aortic aneurysm (AAA) repair.
Methods: We queried The American College of Surgeons National Surgery Quality Improvement Program dataset from
2005 to 2009 for open or endoluminal AAA repairs using Current Procedural Terminology and International Classiﬁ-
cation of Diseases, 9th Edition, codes. Operations performed emergently or for ruptured AAA were excluded. VTE was
deﬁned as either deep venous thrombosis or pulmonary embolism requiring treatment within 30 days of operation. VTE
was classiﬁed as occurring in-hospital or postdischarge. Univariate and multivariable analyses of VTE were performed
relative to preoperative and operative risks, including type of repair.
Results: Query of the dataset yielded 12,469 patients: 8502 endoluminal (68.2%) and 3967 (31.8%) open repairs. Mean
patient age was 73.2 ± 8.7 (standard deviation) years, and 19.8% of patients were women. The 30-day VTE rate was 1.1%
(n [ 135). Of VTE cases, 30% (40/135) were diagnosed after discharge from the surgical hospitalization. The post-
discharge VTE rate was 0.3% after both open and endoluminal repairs. The in-hospital VTE rate was higher in the open
group (1.6% vs 0.4%; P < .001), as was median length of stay (7 days vs 2 days; P < .001). Independent preoperative
predictors of in-hospital VTE were dyspnea, serum albumin (protective), and history of peripheral vascular disease. With
preoperative risk adjustment, in-hospital VTE risk increased with duration of operation and number of units of blood
transfused. Open repairs were associated with higher risk for VTE than endoluminal repairs (odds ratio, 1.91; 95%
conﬁdence interval, 1.10-3.33; P[ .022). VTE was associated with increased 30-day mortality from 1.9% (232/12,102)
in patients without VTE to 4.4% (6/135) in patients with VTE (c2 P [ .035).
Conclusions: VTE after AAA repair was infrequent but was associated with higher mortality, and one-third of VTEs were
diagnosed after discharge. Open AAA repair increased risk for in-hospital VTE compared with endoluminal repair.
Patients with the identiﬁed risk factors may beneﬁt from pharmacologic thromboprophylaxis after AAA repair. Phar-
macologic thromboprophylaxis may be unnecessary after endoluminal repair. (J Vasc Surg 2013;57:678-83.)Observational studies have examined venous thrombo-
embolism (VTE) risk in patients undergoing vascular
surgery, but most are limited by small sample size.1,2 There
is insufﬁcient information regarding the use of prophylactic
anticoagulation for patients undergoing aortic surgery.
Recommendations have not been clearly established for
patients undergoing elective open repair of abdominal aortic
aneurysm (AAA), although this setting could be considered
high risk for VTE. These patients have several risk factors
including advanced age, long duration of surgery and bed
conﬁnement, and possible use of blood transfusions. More
recently, Hollyoak et al3 reported the results of a predis-
charge duplex ultrasound study of 50 patients undergoing
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://dx.doi.org/10.1016/j.jvs.2012.09.048a higher rate of deep venous thrombosis (DVT) in patients
undergoing aortic surgery (41%) compared with patients
undergoing peripheral artery surgery (18%). We sought to
determine the incidence, timing, and risk factors for VTE
within 30 days of elective open or endoluminal graft (ELG)
AAA repair. The American College of Surgeons National
Surgery Quality Improvement Program (ACS NSQIP) has
rigorous follow-up for 30 days after surgery on a large system-
aticmulticenter sample of vascular surgery patients; therefore,
it provided a clinically robust dataset for the analysis.4,5
METHODS
A prospective, systematic study of patients undergoing
major surgical procedures was performed at >200 hospitals
as part of the ACS NSQIP.6 In participating hospitals,
a data coordinator collected>50 preoperative patient char-
acteristics, intraoperative processes of care, and 22
uniformly deﬁned postoperative adverse occurrences (in-
cludingdeath) up to 30days after the operation. The system-
atic sample was performed by including the ﬁrst 40
operations in each 8-day cycle per coordinator. Risk and
outcome variables were rigorously deﬁned, and coordinators
had previously completed in-depth training on all study deﬁ-
nitions. Phone calls, letters, and review of clinic/hospital
medical records were used to obtain 30-day follow-up infor-
mation. Regular conference calls, annual meetings, and site
visits were used to maintain data reliability. Additional
Table I. Characteristics of patients undergoing elective
AAA repair
Characteristic
Number of patients 12,469
Endoluminal graft repair 68.2%
Open repair 31.8%
Transfer from other facility 2.4%
Mean age, years (6 SD) 73.2 6 8.7
Female 19.8%
Race
White 85.8%
Black 3.7%
Unknown/other 10.5%
ASA class IV or V 19.9%
Functionally dependent
(partially or fully)
3.8%
Mean BMI (6 SD) 27.9 6 5.5
Dyspnea at rest or with
moderate exertion
24.5%
Medically treated hypertension 80.8%
Current smoker 33.1%
Medically treated diabetic
(oral or insulin)
14.0%
Prior cardiac stent or operation 38.3%
Cardiac history (CHF, cardiac
arrest or infarct)
3.9%
Preoperative pulmonary compromise
(pneumonia, severe COPD,
mechanical ventilation)
19.0%
History of stroke, TIA, or hemiplegia 15.3%
Peripheral vascular disease (rest pain,
gangrene, prior revascularization)
5.5%
Hematocrit <38% 28.1%
Creatinine >1.2 mg/dL 30.1%
Steroid treatment for chronic condition 3.6%
Bleeding disorder, including undocumented
timely discontinuance of blood thinners
9.6%
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesi-
ologists; BMI, body mass index; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; SD, standard deviation; TIA, tran-
sient ischemic attack.
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Patients <18 years old and patients with admissions for
trauma were excluded.
Adverse occurrences included DVT and pulmonary
embolism (PE) deﬁned by ACS NSQIP protocol. DVT
was deﬁned as follows: “Identiﬁcation of a new blood
clot or thrombus within the venous system conﬁrmed by
a duplex, venogram, or CT scan. The patient must be
treated with anticoagulation therapy and/or placement of
a vena cava ﬁlter or clipping of the vena cava.” PE was
deﬁned as follows: “Lodging of a blood clot in a pulmonary
artery with subsequent obstruction of blood supply to
the lung parenchyma. Identiﬁed with a V-Q scan inter-
preted as high probability of pulmonary embolism or
a positive CT spiral exam, pulmonary arteriogram, or
CT angiogram.”7
We queried the ACSNSQIP dataset from 2005 to 2009
for AAA repairs (primary procedure Current Procedural
Terminology code 34800, 34802, 34803, 34804, 34805,
35081, 35091 or 35102) with operative diagnosis of AAA
without mention of rupture (International Classiﬁcation of
Diseases, 9th Edition, code 441.4). We excluded emergent
operations. We deﬁned VTE as occurrence of DVT or PE.
A univariate comparison of length of stay and VTE in
open vs ELG AAA repair was performed using rank and
c2 tests. Mortality in patients experiencing VTE vs patients
who did not experience VTE was similarly analyzed.
Stepwise multivariable logistic regression of in-hospital
VTE was performed considering >40 ACS NSQIP preop-
erative risk factors (P for entry <.05; P for exit >.10).
Factors considered but not reported are shown in
Supplementary Table I (online only). Intraoperative vari-
ables (open vs ELG repair, operative duration, wound class,
and intraoperative transfusion) were similarly regressed
with the independent preoperative risk variables ﬁxed in
the model. A second multivariable analysis for 30-day
mortality was similarly performed with VTE occurrence
forced into the ﬁnal model after preoperative and operative
mortality risk factors were determined.
Using a modiﬁcation of the methods of Le Gall et al,8
risk point values were assigned by rounding the odds ratio
(OR) associated with each independent positive risk factor
off to the nearest integer (eg, OR of 2.254 would add þ2
to the ﬁnal risk score). The risk index for each patient was
calculated by summing the risk factor points. The risk index
values were divided into discrete ranges of 0, 1-3, 4-7, 8-
10, and >10. VTE rates were calculated for each group
and graphed. All statistical analyses were performed using
SPSS Version 18 (IBM Corp, Armonk, NY) statistical soft-
ware with P < .05 set as signiﬁcant.
RESULTS
Our query yielded 12,469 patients: 8502 ELG (68.2%)
and 3967 (31.8%) open repairs. The mean age was 73.2 6
8.7 (standard deviation) years, and 2466 patients (19.8%)
were women. Slightly >80% received medical treatment
for hypertension, 33% were current smokers at the time
of surgery, and 38% had prior cardiac stents or operations.Other clinical risk factors are shown in Table I. The DVT
rate within 30 days of operation was 0.9% (n ¼ 106),
and the PE rate was 0.3% (n ¼ 36). Diagnosis of both
was rare (n ¼ 7), and the combined DVT or PE rate
(VTE) was 1.1% (n ¼ 135).
The median postoperative days to VTE diagnosis was 8
(interquartile range, 4-15 days) (Fig 1). Of VTEs, 30%
(40/135) were diagnosed after discharge from the surgical
hospitalization, and the postdischarge VTE rate was similar
(0.3%) in open vs ELG repairs. The in-hospital VTE rate
was higher in the open group (1.6% vs 0.4%; P < .001)
(Table I) as was median length of stay (7 vs 2 days; P <
.001). The 30-day mortality was 1.9% (238/12,469) and
was higher in the open repair group. VTE was associated
with increased 30-day mortality from 1.9% (232/12,102)
in patients without VTE to 4.4% (6/135) in patients
with VTE (c2 P ¼ .035). After multivariable risk adjust-
ment for preoperative and operative risks, VTE was not
an independent predictor of mortality (see mortality model
in Supplementary Table II, online only).
Fig 1. Number of patients with diagnosis and treatment of venous
thromboembolism (VTE) by postoperative day and discharge
status in patients who underwent elective abdominal aortic aneu-
rysm (AAA) repair.
Table II. VTE rates after elective open vs endoluminal
graft AAA repair
Type of repair
PELG Open
Number of cases 8502 3967
30-day mortality 1.2% 3.4% <.001
Median length of
hospital stay, days
2 7 <.001
In-hospital VTE rate 0.4% 1.6% <.001
30-day postdischarge VTE rate 0.3% 0.3% .805
AAA, Abdominal aortic aneurysm; ELG, endoluminal graft; VTE, venous
thromboembolism.
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only three independent ACS NSQIP preoperative predictors
of VTE (Table II); this is after consideration of >40 risk
factors shown in Tables I and III and Supplementary
Table I. Dyspnea at rest or with moderate exertion had an
OR of 1.71 (95% conﬁdence interval [CI], 1.12-2.61;
P ¼ .005). Serum albumin #3 g/dL had an OR of 2.60
(95% CI, 1.12-2.61; P ¼ .007). American Society of Anes-
thesiologists class IV or V had an OR of 1.63 (95% CI,
1.06-2.53; P ¼ .028). Operative transfusion of $5 units
had an OR for VTE of 2.63 (95% CI, 1.27-3.33; P ¼
.009), and operative duration >4 hours had an OR for
VTE of 3.66 (CI, 1.43-9.42; P ¼ .007). After preoperative
and intraoperative risk adjustment, open repair had higher
risk for in-hospital VTE (OR, 1.91; 95% CI, 1.10-3.33;
P ¼ .022). The Hosmer-Lemeshow statistic (P ¼ .306)
indicated good model ﬁt.
Risk points for each independent risk factor are also
shown in Table III. A risk index derived from the sum of
risk points for each patient showed “good”9 discrimination
in predicting VTE (c-index, 0.758; 95% CI, 0.709-0.807;
P < .001). VTE rates are shown by risk point groups in
Fig 2. Patients with no risk factors experienced VTE rates
of 0.2%, which increased sixfold to 1.2% in patients with 4
to 7 risk points and to 4.6% in patients with$11 risk points.
DISCUSSION
We used the ACS NSQIP database to examine the inci-
dence, timing, and risk factors for symptomatic VTE after
elective AAA repair. Overall, symptomatic VTE developed
in a small number of patients with 30% of postoperative
VTE occurring after discharge. The risk of in-hospital
VTE was greater for open vs ELG repair. We identiﬁed
preoperative and intraoperative risk factors predisposing
to postoperative VTE and created a risk index that showed
good discrimination in predicting in-hospital VTE.
Risk factors for VTE in vascular surgery are not well
established. The report by de Maistre et al10 identiﬁed
delay to prescribe thromboprophylaxis and transfusion offresh frozen plasma as risk factors for DVT. Some authors
believe that the use of intraoperative anticoagulation at
least partially mitigates the prothrombotic stimulus of
surgery. Nevertheless, population-based studies indicate
that risk of symptomatic VTE in the 12 weeks after surgery
is not very different in patients undergoing vascular surgery
(1 in 115) compared with patients undergoing surgery for
cancer (1 in 85).10,11 Data from the California Discharge
Data Set reported that the risk of symptomatic VTE within
91 days of vascular surgery was approximately 1.7%12; this
is similar to our ﬁndings. These studies as well as ours focus
on symptomatic VTE; studies that rely on venography or
duplex ultrasound of all postoperative patients report
higher incidence. Olin et al,13 using bilateral venography,
determined that 18% of 50 consecutive patients under-
going AAA resection had DVT. Although many episodes
of VTE are asymptomatic, there is a highly signiﬁcant asso-
ciation of asymptomatic DVT and 90-day mortality.14 The
studies done in patients undergoing vascular surgery to
determine the need for VTE prophylaxis were limited by
small samples, and results were inconclusive. Because of
these limitations, current American College of Chest Physi-
cians15 guidelines for vascular surgery patients are based on
application of estimates of relative risk from higher quality
studies in general and abdominal surgery. The guidelines
also take into account the consequences of postoperative
bleeding as stated in the 9th edition15:
“For general and abdominal-pelvic surgery patients at
moderate risk for VTE (w3.0%; Rogers score,>10; Caprini
score, 3-4) who are at high risk for major bleeding com-
plications or those in whom the consequences of bleeding
are thought to be particularly severe, we suggest mechanical
prophylaxis, preferably with [intermittent pneumatic com-
pression] IPC, over no prophylaxis (Grade 2C). For high-
VTE-risk general and abdominal-pelvic surgery patients
who are at high risk for major bleeding complications or
those in whom the consequences of bleeding are thought
to be particularly severe, we suggest use of mechanical
prophylaxis, preferably with IPC, over no prophylaxis until
the risk of bleeding diminishes and pharmacologic prophy-
laxis may be initiated (Grade 2C).”
The role for chemical prophylaxis is not clearly deﬁned
in these guidelines. A few thromboprophylaxis studies
Fig 2. Venous thromboembolism (VTE) rates by risk index points.
Table III. Multivariable preoperative and operative risk factors for in-hospital VTE in patients undergoing elective AAA
repair
Variable Incidence OR (95% CI) P Risk points
Dyspnea at rest or with moderate exertion 3049 (24.5%) 1.71 (1.12-2.61) .005 2
Known serum albumin, g/dLa
$3.81 10,026 (80.4%) Reference 0
3.41-3.80 1446 (11.6%) 1.02 (0.52-1.99) .961 0
3.01-3.40 621 (5.0%) 1.37 (0.59-3.19) .467 0
#3.00 376 (3.0%) 2.60 (1.12-2.61) .007 3
ASA class IV or V 2480 (19.9%) 1.63 (1.06-2.53) .028 2
Intraoperative transfusion PRBCs vs none 8551 (68.6%) Reference
1-2 units 2200 (17.6%) 1.36 (0.73-2.54) .340 0
3-4 units 978 (7.8%) 1.81 (0.88-3.71) .109 0
$5 units 740 (5.9%) 2.63 (1.27-5.44) .009 3
Open vs ELG repair 3967 (31.8%) 1.91 (1.10-3.33) .022 2
Wound class not clean 320 (2.6%) 2.19 (1.07-4.50) .033 2
Operative duration vs #2 hours 3133 (25.1%) Reference
2.01-3 hours 4350 (34.9%) 2.25 (0.91-5.58) .080 0
3.01-4 hours 2586 (20.7%) 2.50 (0.97-5.58) .056 0
>4 hours 2400 (19.2%) 3.66 (1.43-9.42) .007 4
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; CI, conﬁdence interval; ELG, endoluminal graft; OR, odds ratio; PRBCs,
packed red blood cells; VTE, venous thromboembolism.
P values are for ﬁnal model.
aSerum albumin values missing in 51% of patients were assigned reference values.
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procedures. In a study by Belch et al16 of 24 patients under-
going elective aortic surgery, patients receiving subcuta-
neous heparin had excess bleeding complications, and
DVT occurred in six control patients not receiving heparin
and in two patients receiving heparin. In this group of
patients undergoing major vascular surgery, the risk of
bleeding owing to heparin outweighed the potential beneﬁt
of thrombotic prophylaxis. Another study randomly
assigned 100 patients undergoing aortic reconstruction for
aneurysmal or occlusive disease to receive DVT prophylaxis
(treatment group) or no prophylaxis (control group).17
The incidence of proximalDVT in patients undergoing elec-
tive aortic reconstruction was low compared with patients
undergoing other major intra-abdominal general surgical
procedures, and the use of DVT prophylaxis did not reduce
the risk of postoperative proximal DVT in this study.
It is possible that a customized approach based on indi-
vidual patient risk proﬁle may be best. As a result of the rela-
tive lack of clinical evaluation of individualized therapy
compared with group-speciﬁc protocols as well as the
complexity and variability of individualized risk assessment,
theAmericanCollege ofChest Physicians guidelines support
the use of group-speciﬁc prophylaxis. However, it may be
that different clinical conditions are associated with varying
individual risk in selected patients. Scarborough et al18 re-
ported a scoring system to predict the risk of postoperative
VTE after openAAA repair. Independent predictors of post-
operative VTE included ruptured aneurysmal disease, pro-
longed operative time, obesity, preoperative dyspnea, and
long-term steroid usage. In our review, we also identiﬁed
dyspnea and prolonged operative time as risk factors.
The approach of vascular surgeons to this problem
is not uniform. Moussa et al19 reported a questionnairesurvey study from surgeons in the United Kingdom. There
was wide variation in the VTE prophylaxis regimen used by
the individual surgeons, but 97% routinely administered
low-molecular-weight heparin postoperatively after open
or endoluminal AAA repair. Our data indicate that the
rate of VTE after open repair is 1.9% vs 0.7% for EVAR.
The risk of in-hospital VTE is signiﬁcantly higher after
open repair; it is not likely that routine chemoprophylaxis
is beneﬁcial for patients undergoing ELG who are at low
risk for VTE. The identiﬁcation of risk factors may help
determine further the need for thromboprophylaxis. The
preoperative and intraoperative risk factors we identiﬁed
were dyspnea, low serum albumin, intraoperative transfu-
sion of >5 units of packed red blood cells, and operative
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VTE has also been reported in cancer patients.20-22
In our patient population, we observed that 30% of
symptomatic VTE occurred after discharge; this might
reﬂect the shorter hospital stay of patients undergoing
ELG, which has a median length of stay 2 days compared
with 7 days for open repair. Nevertheless, the risk of VTE
complications has been shown to extend for several months
beyond hospital discharge.23 There were no in-hospital VTE
events in a study assessing the effect of thromboprophylactic
regimens of varying duration on the incidence of VTE in 417
patients undergoing colorectal surgery between 2005 and
2009.24 The incidence of symptomatic VTE from hospital
admission for surgery to 12 months after was 2.4%. Most
events occurred in the 3-month period after discharge.24
This retrospective review of a surgical registry has
unknown selection and patient bias, which limits any
conclusions about causality. The database does not provide
information about use or timing of thromboprophylaxis or
about time to ambulation or long-term outcomes. Like-
wise, it tracks only symptomatic VTE without mention of
the protocol used to evaluate patients for possible DVT.
We believe that the combined VTE rate of 1.1% underesti-
mates the true incidence because most lower extremity
DVTs are asymptomatic. Using duplex ultrasound in all
postoperative patients, de Maistre et al10 reported that
8.1% of patients undergoing elective open or ELG AAA
repair developed postoperative DVT. These limitations
are mitigated by the large prospectively enrolled cohort
from hundreds of hospitals and surgeons.
CONCLUSIONS
Incidence of VTE after AAA repair was infrequent;
however, VTE risk persists after discharge. Our analysis of
data from the ACS NSQIP database better deﬁnes the risk
of VTE after elective AAA repair, and clinicians may
beneﬁt from the risk index developed. Patients with the
identiﬁed risk factors may beneﬁt from pharmacologic
thromboprophylaxis after AAA repair, and this information
may assist surgeons with decision making regarding throm-
boprophylaxis. ELG provided protection from VTE
compared with open repair. It may be reasonable to withhold
heparin thromboprophylaxis from patients undergoing ELG
repair of nonruptured AAA if they do not have any of the
listed risk factors given their low VTE risk of 0.2%.
The ACS NSQIP and the hospitals participating in the
ACS NSQIP are the sources of the data used herein; they
have not veriﬁed and are not responsible for the statistical
validity of the data analysis or the conclusions derived by
the authors.
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Supplementary Table I (online only). Variables examined as possible predictors of VTE or mortality not listed in Tables
I or III
Variable Variable
Do-not-resuscitate status Central nervous system tumor
Ascites Disseminated cancer
Esophageal varices Recent chemotherapy
Quadriplegia/paraplegia Recent radiotherapy
Preoperative renal failure Hematocrit >45%
On dialysis PTT >35
Impaired sensorium Platelet count >400
Preoperative open wound/infection INR >1
Preoperative SIRS or sepsis WBC count #4,500 mm3
Reported EtOH consumption >2 drinks/day WBC count >11,000 mm3
Recent weight loss >10% of body mass Preoperative transfusion >4 units PRBCs
EtOH, Ethyl alcohol; INR, international normalized ratio; PRBCs, packed red blood cells; PTT, partial thromboplastin time; SIRS, systemic inﬂammatory
response syndrome; VTE, venous thromboembolism; WBC, white blood cell.
Supplementary Table II (online only). Multivariable preoperative and operative risk factors for 30-day mortality in
patients undergoing elective AAA repair
Variable Incidence OR (95% CI) P
Partial or full functional dependence
preoperatively
474 (3.8%) 1.93 (1.25-2.99) .003
Age group
#60 956 (7.7%) Reference
61-70 3601 (28.9%) 0.99 (0.45-2.18) .988
71-80 5263 (42.2%) 2.03 (0.98-4.24) .058
$81 2649 (21.2%) 3.10 (1.46-6.55) .003
ASA class IV or V 2480 (19.9%) 1.40 (1.04-1.87) .026
Known serum albumin, g/dLa
$3.81 10,026 (80.4%) Reference
3.41-3.80 1446 (11.6%) 1.48 (1.02-2.15) .038
3.01-3.40 621 (5.0%) 1.19 (0.68-2.07) .541
#3.00 376 (3.0%) 1.94 (1.17-3.21) .010
Dyspnea at rest or with moderate exertion 3049 (24.5%) 1.73 (1.31-2.29) <.001
Creatinine >1.2 mg/dL 3752 (30.1%) 1.62 (1.23-2.13) .001
History of revascularization or current
gangrene/rest pain
788 (6.3%) 1.72 (1.15-2.59) .009
Female gender 2466 (19.8%) 1.40 (1.04-1.89) .027
Recent weight loss >10% 214 (1.7%) 1.96 (1.06-3.63) .033
Steroid use for chronic condition 451 (3.6%) 1.71 (1.01-2.92) .045
Prior cardiac procedure 4778 (38.3%) 1.18 (0.89-1.55) .248b
BMI group
#25.00 3739 (30.0%) Reference
25.01-30.00 5069 (40.7%) 0.68 (0.50-0.92) .014
30.01-35.00 2512 (20.1%) 0.66 (0.44-0.98) .041
$35.01 1149 (9.2%) 0.69 (0.40-1.17) .168
Intraoperative transfusion PRBCs vs none 8551 (68.6%) Reference
1-2 units 2200 (17.6%) 1.90 (1.29-2.80) .001
3-4 units 978 (7.8%) 2.68 (1.72-4.18) <.001
$5 units 740 (5.9%) 6.38 (4.22-9.64) <.001
Operative duration, hours
#2 3133 (25.1%) Reference
2.01-3 4350 (34.9%) 1.27 (0.77-2.10) .350
3.01-4 2586 (20.7%) 1.58 (0.93-2.68) .095
>4 2400 (19.2%) 2.36 (1.39-4.00) .001
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; BMI, body mass index; CI, conﬁdence interval; OR, odds ratio; PRBCs,
packed red blood cells.
aSerum albumin values missing in 51% of patients were assigned reference values.
bPreoperative risk factors entered into the model with P < .05 and were ﬁxed in the model as adjustors before consideration of the intraoperative factors.
Preoperative risk P values are shown for ﬁnal model.
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